Skip to main content
INCY
NASDAQ Industrial Applications And Services

Incyte Details Strong 2025 Performance, Robust Pipeline, and Annual Meeting Proposals

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$96.2
Mkt Cap
$19.452B
52W Low
$57.77
52W High
$112.29
52W Position info
67% above low
Off High info
14% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

INCY sits 67% above its 52-week low of $57.77.

Summary

Incyte filed its definitive proxy statement, detailing strong 2025 financial results, a robust clinical pipeline with significant future potential, and proposals for its upcoming annual shareholder meeting.


Key Events · Corporate Governance and Compliance · INCY

  • Strong 2025 Financial Performance

    Incyte reported total revenues of $5.14 billion for 2025, a 21% year-over-year increase, with core business net sales (excluding Jakafi) growing 53% to $1.26 billion.

  • Robust Clinical Pipeline Advancement

    The company is advancing seven high-value assets with potential for over $10 billion in non-risk adjusted sales and expects to have 14 pivotal trials underway by the end of 2026.

  • Annual Shareholder Meeting Scheduled

    The annual meeting will be held on June 8, 2026, to elect eight directors, conduct an advisory vote on executive compensation, and ratify Ernst & Young LLP as the independent auditor.

  • Executive Compensation Details

    CEO William J. Meury's 2025 total compensation was over $32 million, with a pay ratio of 110.47 to 1 compared to the median employee, structured with a significant portion tied to performance.


Analysis · INCY · Industrial Applications And Services

This definitive proxy statement provides a comprehensive overview of Incyte's 2025 financial and operational achievements, alongside its strategic outlook and corporate governance matters. The detailed performance highlights, including significant revenue growth and an advancing clinical pipeline, reinforce the positive sentiment from concurrent earnings reports. While executive compensation is substantial, the company emphasizes its performance-based structure and robust governance. Investors should note the strategic direction outlined for the pipeline and the upcoming shareholder votes on director elections and executive pay.

At the time of this filing, INCY was trading at $96.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.5B. The 52-week trading range was $57.77 to $112.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Jul 28, 2026, 8:58 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $119.10
Real-time Price: $130.00 info
Change: +$10.90 (+9%) info
Market Cap: $25.972B info
INCY
Jul 28, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $118.50
Real-time Price: $130.00 info
Change: +$11.50 (+10%) info
Market Cap: $25.972B info
INCY
Jul 06, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $115.62
Real-time Price: $130.00 info
Change: +$14.38 (+12%) info
Market Cap: $25.972B info
INCY
Jul 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $115.62
Real-time Price: $130.00 info
Change: +$14.38 (+12%) info
Market Cap: $25.972B info
INCY
Jul 06, 2026, 8:39 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $116.25
Real-time Price: $130.00 info
Change: +$13.75 (+12%) info
Market Cap: $25.972B info